Trials / Unknown
UnknownNCT04796441
Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd. · Industry
- Sex
- All
- Age
- 2 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is an open single-arm clinical study aimed at evaluating the efficacy and safety of universal γδT cell injection in the treatment of patients with relapsed AML after transplantation
Detailed description
Main purpose: To evaluate the safety and effectiveness of universal CAR-γδT cell injection in the treatment of patients with relapsed AML after transplantation Secondary purpose: to investigate the in vivo dynamics characteristics of universal CAR-γδT cells after infusion and explore reasonable therapeutic doses through climbing tests in different dose groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAR-γδT | Biological: CAR-γδT; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis; |
Timeline
- Start date
- 2020-12-16
- Primary completion
- 2021-12-16
- Completion
- 2022-02-16
- First posted
- 2021-03-12
- Last updated
- 2021-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04796441. Inclusion in this directory is not an endorsement.